<DOC>
	<DOCNO>NCT00002627</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may able replace immune cell destroy chemotherapy use kill tumor cell , allow high dos chemotherapy use . PURPOSE : Phase I/II trial study effectiveness paclitaxel add high-dose combination chemotherapy follow peripheral stem cell transplantation treat woman breast cancer high risk relapse .</brief_summary>
	<brief_title>Addition Paclitaxel High-Dose Combination Chemotherapy Treating Patients With High-Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Estimate maximum tolerate dose paclitaxel give high-dose carboplatin/cyclophosphamide autologous peripheral blood stem cell support woman high-risk stage II/III breast cancer . II . Assess nonhematologic toxicity associate combination . III . Assess progression-free overall survival patient follow treatment . OUTLINE : This dose-finding study . All patient undergo collection peripheral blood stem cell ( PBSC ) granulocyte colony-stimulating factor ( G-CSF ) mobilization prior high-dose chemotherapy . Cohorts 3-5 patient treat successively high dose level paclitaxel maximum tolerate dose ( MTD ) find . Paclitaxel give single 6-hour infusion , follow fixed dos high-dose cyclophosphamide 2 day , carboplatin 3 day . Four day later , patient receive PBSC G-CSF hematopoietic reconstitution . Additional patient enter MTD . Patients follow every 3 month 1 year , every 4 month 1 year , every 4-6 month thereafter . PROJECTED ACCRUAL : It expect 24-30 patient accrue ; study duration 1-1.5 year anticipate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose adenocarcinoma breast follow stage : Stage II/IIIA disease 4 involved axillary lymph node Stage IIIB Inflammatory No bone marrow involvement document bone marrow aspiration biopsy Prior breast cancer allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 65 Sex : Women Menopausal status : Not specify Performance status : Karnofsky 70 % 100 % Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Renal : Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction least 50 % MUGA No abnormal cardiac conduction document second thirddegree heart block bundle branch block Pulmonary : DLCO least 60 % predict Other : Not HIV positive No history second malignancy within 5 year except : Nonmelanomatous skin cancer In situ carcinoma cervix No pregnant woman PRIOR CONCURRENT THERAPY : At least 3 course induction therapy require , regimen discretion investigator No disease progression induction</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2000</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>